General Information
BounceWatch is an independent company data service, not affiliated with Aptus Biotech. To contact Aptus Biotech, visit aptusbiotech.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Aptus Biotech compare?
A PDF of Aptus Biotech and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Aptus Biotech soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
From the desk
Is Aptus Biotech on your competitive set?
Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.
Book a 7-day ReadoutDiscover More
Spain Market
Biotechnology
About Aptus Biotech
Business keywords: Biotech Start-up, Aptamers, Therapeutic Tools, Diagnostic Tools, SELEX Method, Drug Discovery, Oligonucleotide, Biomedical Applications, Research and Development, Biotechnological Applications, Aptamer Selection, Chemical Synthesis, Biomedical Research, Innovative Technology, Ramon y Cajal Hospital Foundation
No funding data available for Aptus Biotech yet.
Aptus Biotech Alternatives & Competitors
View All AlternativesChemistry platform built on proprietary chiral chemical space, progressing hits to small molecule le...
Cutting-Edge Pharmacological Treatment for Obesity
Bristol-Myers Squibb acquired Flexus for $800M upfront & $450M in potential earnouts in 2015.
FAQ About Aptus Biotech
Source: BounceWatch company record for Aptus Biotech, https://www.bouncewatch.com/company/aptus-biotech, updated 28 October 2024. When citing, please name BounceWatch and link this page.